Sensidose Overview

  • Founded
  • 1998

  • Status
  • Public

  • Employees
  • 7

  • Stock Symbol

Stock Symbol
  • Share Price
  • $0.34

  • (As of Wednesday Closing)

Sensidose General Information


Sensidose AB is a pharmaceutical company that has developed a system for individualized dosing of tablets, a medical treatment using a dosing device pre-programmed for the patient. The system consists of tablets, containing low doses in each individual tablet. Its product comprises MYFID and FLEXILEV. The micro- tablets are retrieved using an automated dispenser. The dispenser has an inbuilt alarm, delivers doses at the programmed time point, and registers all doses delivered as well as disease symptoms with the help of easy-to-use scales.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Other Devices and Supplies
Stock Exchange
Primary Office
  • Vetenskapsvägen 10
  • 191 38 Sollentuna
  • Sweden
+46 010-707 00 00

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Sensidose Stock Performance

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.34 $0.34 $0.30 - $0.45 $4.11M 12M 9.4K -$0.04

Sensidose Financials Summary

In Thousands,
TTM 31-Dec-2021 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2017 31-Dec-2017
Revenue 811 811 755 309
EBITDA (292) (292) (527) (818)
Net Income (470) (470) (859)
Total Assets 1,735 1,735 1,768
Total Debt 432 432 547
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Sensidose Valuation & Funding

Deal Type Date Amount Valuation/
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Sensidose‘s full profile, request access.

Request a free trial

Sensidose Patents

Sensidose Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3065105-A1 Systems for evaluating dosage parameters Pending 31-May-2017 000000000
GB-201708624-D0 System for evaluating dosage parameters Ceased 31-May-2017 000000000
EP-3635729-A1 Systems for evaluating dosage parameters Pending 31-May-2017 000000000
US-20200168310-A1 Systems for evaluating dosage parameters Pending 31-May-2017 000000000
US-11040013-B2 Compacted powder Active 12-Nov-2015 A61K9/2072 0
To view Sensidose’s complete patent history, request access »

Sensidose Executive Team (7)

Name Title Board Seat Contact Info
Kristofer Svensson Chief Financial Officer
Per Holm Chief Technology Officer
Sten-Magnus Aquilonius Ph.D Co-Founder & Board Member
Jack Spira Ph.D Chief Executive Officer & Board Member
You’re viewing 4 of 7 executive team members. Get the full list »

Sensidose Board Members (11)

Name Representing Role Since
Bo-Ragnar Tolf Ph.D Self Board Member 000 0000
Ingemar Kihlström Sensidose Co-Chairman 000 0000
Jack Spira Ph.D Self Chief Executive Officer & Board Member 000 0000
Lasse Tenerz Self Board Member 000 0000
Per Nilsson Sensidose Co-Chairman 000 0000
You’re viewing 5 of 11 board members. Get the full list »

Sensidose Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial